An interventional study of VR-based cognitive training program and VR-based attention control in Intensive Care Unit Delirium, Intensive Care Acquired Cognitive Impairment and Post Intensive Care Unit Syndrome, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Indiana University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Cognitive Dysfunction by Indiana University — 6 open to participants now, 8 under way, none of them phase 3. Cognitive Dysfunction · Indiana University.
Among the 23 studies in Cognitive Dysfunction by Indiana University, this one is the 13th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 22nd registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →6 of the 23 studies in Cognitive Dysfunction by Indiana University are open now, in 1 country. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 65+
Indiana University · Sites in United States
Ages 50+
Indiana University · Sites in United States
Ages 45+
Indiana University · Sites in United States
Ages 18–75 · Healthy volunteers
Indiana University · Sites in United States
Ages 35–75
By country, each count listing its studies:
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 143 across the 20 interventional studies, 682 across the 3 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
Indiana University is the lead sponsor of 991 studies on the registry; 202 are open to participants now.
Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.
6 of the studies in Cognitive Dysfunction by Indiana University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06403345Indiana UniversityA Feasiblity Study of Green Activity Program for People Living With Memory Challenges | 2026-11-30 |
| NCT03507257Indiana UniversityLongitudinal Early-onset Alzheimer's Disease Study Protocol | 2027-01-01 |
| NCT07496255Indiana UniversityVirtual Reality Cognitive Intervention for Critically Ill Delirium Survivors (VR-Cog) | 2027-02-15 |
| NCT07499570Indiana UniversityMulti-modal Large Language Model-Empowered Talk Therapy for Older Adults With ADRD | 2027-03-01 |
| NCT05601817Indiana UniversityVirtual Reality and Computerized Cognitive Intervention for Mild Cognitive Impairment in Heart Failure | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 23 studies in Cognitive Dysfunction by Indiana University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to measure the feasibility, acceptability of virtual reality (VR) brain games and estimate their effect on memory, attention, and mood for ICU survivors. The VR program will be used at home through a headset and hand controls.
Acute respiratory failure (ARF) accounts for 2 million admissions to adult intensive care units (ICUs) in the United States annually, and up to 80% of older adults with ARF suffer delirium, a form of ICU-related acute brain dysfunction. Delirium doubles the risk for new cognitive impairment or dementia within 12 months of ICU discharge. In addition, delirium survivors frequently develop related mental health and quality of life impairments. Unfortunately, there are few effective or scalable interventions to improve cognitive outcomes for ICU survivors.
Primary Objective Aim 1: Measure the feasibility, acceptability, and adherence of VR-Cog in older adult ICU delirium survivors at risk for ICU-acquired MCI and ADRD.
Secondary Objective Aim 2: Estimate the effect of VR-Cog on cognitive performance among older adult ICU delirium survivors.
Tertiary/Exploratory/Correlative Objectives Aim 3: Explore the effects of VR-Cog on mental health (depression and anxiety).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: VR-based cognitive training program
Device: VR-based attention control
VR-Cog features HomeTown Bound, a suite of 18 modules organized into four training categories: attention, processing speed, memory, and visuospatial.
Also known as: VR-Cog
VR-AC consists of a library of 9 nature scenes (content provided by Nature Treks VR).
Also known as: VR-AC
Measure the feasibility of VR-Cog in older adult ICU delirium survivors
Feasibility will be measured by the percentage (%) of intervention sessions delivered to participants, with greater than or equal to 80% of intervention sessions completed defining feasibility.
Time frame: Feasibility will be measured at 4 weeks (the end of the intervention period)
Measure the acceptability of VR-Cog in older adult ICU delirium survivors
Acceptability will be defined as scores of 8 or greater on each subscale of the Senior Technology Acceptance Model (STAM, Short Form with 14-items). The four subscales of the STAM measure attitudes towards technology (perceived use and effectiveness), control beliefs (ability to use the technology and complete tasks), gerontologic anxiety (feeling apprehensive or hesitant with technology applications), and general health (ability to concentrate, satisfaction with general health).
Time frame: Acceptability will be measured at 4 weeks (the end of the intervention period)
Measure the adherence to VR-Cog in older adult ICU delirium survivors
Adherence to the protocol will be assessed through rates of retention at end of 4-week intervention (80% among participants alive and out of the hospital) and completion of outcomes assessments (80% among participants alive and out of the hospital).
Time frame: Adherence will be measured at 4 weeks (the end of the intervention period)
Estimate the effect of VR-Cog on cognitive performance among older adult ICU delirium survivors.
Repeatable Battery for Assessment of Neuropsychological Status (RBANS)
Time frame: Measured at Baseline, 4 weeks (end of intervention period), 3-Month and 6-Month follow up
Explore the effects of VR-Cog on depression
As measured by Patient Health Questionnaire (PHQ-9)
Time frame: Measured at baseline (hospital discharge), 4 weeks (end of intervention period), 3-months and 6-months post-randomization.
Explore the effects of VR-Cog on anxiety
As measured by Generalized Anxiety Disorder (GAD-7) scale
Time frame: Measured at baseline (hospital discharge), 4 weeks (end of intervention period), 3-months and 6-months post-randomization.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 10 months is below that.
Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.